SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.


EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information

LEAVE THIS BLANK

By selecting this, I agree to receive emails from celltelligence.com.

Already have an account? Log in here
RETURN TO HOME
$0
Autologous, BCMA, CAR-T, CD19

GILD: Q1 2021 Earnings Call Summary; JNJ: Cilta-cel MAA Submitted

Here is a brief preview of this blast: On Thursday, April 29, Gilead held their Q1 2021 earnings call (press release / presentation), highlighting the rapid recovery of their cell therapy sales revenue, while discontinuing several Yescarta and Tecartus programs. Furthermore, on Friday, April 30, JNJ announced (press release) cilta-cel’s (BCMA CAR-T) MAA submission to the EMA for r/r multiple myeloma (MM). Below, Celltelligence provides insights on how Gilead may leverage Yescarta’s European expansion to recover and grow market share, while discussing cilta-cel’s potential EU approval timelines.

About The Author

The Celltelligence Team

|
Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.